KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Supernus Pharmaceuticals (SUPN) EBIT Margin: 2011-2025

Historic EBIT Margin for Supernus Pharmaceuticals (SUPN) over the last 15 years, with Sep 2025 value amounting to -31.35%.

  • Supernus Pharmaceuticals' EBIT Margin fell 5460.00% to -31.35% in Q3 2025 from the same period last year, while for Sep 2025 it was -5.42%, marking a year-over-year decrease of 1451.00%. This contributed to the annual value of 12.34% for FY2024, which is 1321.00% up from last year.
  • Supernus Pharmaceuticals' EBIT Margin amounted to -31.35% in Q3 2025, which was down 527.27% from 7.34% recorded in Q2 2025.
  • Supernus Pharmaceuticals' EBIT Margin's 5-year high stood at 24.14% during Q2 2021, with a 5-year trough of -31.35% in Q3 2025.
  • Over the past 3 years, Supernus Pharmaceuticals' median EBIT Margin value was 3.37% (recorded in 2023), while the average stood at 1.00%.
  • Per our database at Business Quant, Supernus Pharmaceuticals' EBIT Margin surged by 2,638bps in 2024 and then crashed by 5,460bps in 2025.
  • Supernus Pharmaceuticals' EBIT Margin (Quarterly) stood at 3.83% in 2021, then spiked by 1,668bps to 20.52% in 2022, then slumped by 2,113bps to -0.61% in 2023, then spiked by 1,290bps to 12.29% in 2024, then tumbled by 5,460bps to -31.35% in 2025.
  • Its last three reported values are -31.35% in Q3 2025, 7.34% for Q2 2025, and -6.85% during Q1 2025.